LivaNova PLC (LIVN) Receives Consensus Rating of “Hold” from Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have received a consensus recommendation of “Hold” from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $78.17.

LIVN has been the topic of several recent research reports. ValuEngine upgraded LivaNova from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. BidaskClub cut LivaNova from a “buy” rating to a “hold” rating in a report on Wednesday. Canaccord Genuity restated a “hold” rating and set a $76.00 target price on shares of LivaNova in a report on Tuesday, December 5th. Piper Jaffray Companies restated a “buy” rating and set a $85.00 target price on shares of LivaNova in a report on Friday, November 3rd. Finally, Needham & Company LLC boosted their target price on LivaNova from $93.00 to $97.00 and gave the stock a “buy” rating in a report on Tuesday, December 5th.

LivaNova (LIVN) opened at $81.76 on Wednesday. The firm has a market capitalization of $3,961.06, a P/E ratio of 69.88, a PEG ratio of 2.44 and a beta of 0.83. LivaNova has a twelve month low of $46.34 and a twelve month high of $88.56. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04.

In other news, Director Alfred J. Novak sold 2,000 shares of LivaNova stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $85.77, for a total transaction of $171,540.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Hugh M. Morrison sold 1,830 shares of LivaNova stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $88.00, for a total transaction of $161,040.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,830 shares of company stock worth $495,530. Corporate insiders own 0.28% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in LIVN. PNC Financial Services Group Inc. raised its position in shares of LivaNova by 9.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock valued at $105,000 after buying an additional 153 shares during the period. Northern Trust Corp raised its position in shares of LivaNova by 26.7% during the 2nd quarter. Northern Trust Corp now owns 392,347 shares of the company’s stock valued at $24,015,000 after buying an additional 82,717 shares during the period. Vanguard Group Inc. raised its position in shares of LivaNova by 13.6% during the 2nd quarter. Vanguard Group Inc. now owns 883,058 shares of the company’s stock valued at $54,052,000 after buying an additional 105,702 shares during the period. Parametric Portfolio Associates LLC raised its position in shares of LivaNova by 106.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 15,042 shares of the company’s stock valued at $921,000 after buying an additional 7,769 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of LivaNova by 55.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 922,229 shares of the company’s stock valued at $56,450,000 after buying an additional 327,395 shares during the period. 88.53% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “LivaNova PLC (LIVN) Receives Consensus Rating of “Hold” from Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/14/livanova-plc-livn-receives-consensus-rating-of-hold-from-analysts.html.

LivaNova Company Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply